Pfizer Stock Price, News & Analysis

Pfizer, MorphoSys, and Incyte announced a clinical trial collaboration to explore the immunotherapeutic combination of Pfizer's TTI-622 with MorphoSys's Monjuvi and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplantation. Pfizer will lead a multicenter Phase 1b/2 study, which is set to take place in North America, Europe, and Asia-Pacific. The initiative addresses significant unmet medical needs in DLBCL treatment and follows promising preclinical data regarding TTI-622's potential efficacy.

Pfizer (NYSE: PFE) has successfully acquired ReViral, a clinical-stage biopharmaceutical company specializing in antiviral therapeutics for respiratory syncytial virus (RSV), for up to $525 million. This acquisition enhances Pfizer's anti-infective pipeline with promising candidates like sisunatovir, which has shown significant efficacy in clinical studies. The potential annual revenue for these programs could exceed $1.5 billion. This strategic move underscores Pfizer's commitment to advancing innovative therapies for serious infectious diseases.

Pfizer Inc. (NYSE: PFE) will host a webcast on June 16, 2022, featuring Mikael Dolsten, Chief Scientific Officer, at the Storebrand Conference: Invest in the Future. The event starts at 11:40 a.m. CEST (5:40 a.m. EDT). Investors can access the live presentation and register through www.pfizer.com/investors. A transcript and replay will be available within 24 hours post-event for 90 days. Pfizer emphasizes its commitment to health advancements and innovation, impacting global healthcare.

Pfizer Inc. (NYSE: PFE) is hosting a webcast discussion with Chief Scientific Officer Mikael Dolsten and Chief Development Officer William Pao at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 8:40 a.m. PDT. Interested parties can access the webcast at www.pfizer.com/investors. The transcript will be available within 24 hours and accessible for at least 90 days. Pfizer focuses on innovative therapies and vaccines to enhance patient lives and actively engages in global health initiatives.

Pfizer Inc. (NYSE: PFE) announced a $120 million investment to expand its manufacturing capabilities at the Kalamazoo, Michigan facility, creating over 250 high-skilled jobs. This initiative aims to enhance production of active pharmaceutical ingredients (APIs) for PAXLOVID, its COVID-19 oral treatment. Since 2017, Pfizer has invested $5 billion in U.S. manufacturing. The Kalamazoo site will become one of the world’s largest API producers, boosting the supply capacity of PAXLOVID to meet growing global demand.

Pfizer Inc. (NYSE:PFE) announced overall survival results from the Phase 3 PALOMA-2 trial evaluating IBRANCE® (palbociclib) with letrozole in first-line treatment for postmenopausal women with HR+, HER2- metastatic breast cancer. With a median follow-up of 90 months, the study showed a median overall survival of 53.9 months for the treatment group versus 51.2 months for the control, though the results were not statistically significant (HR=0.956). The trial's primary endpoint was progression-free survival, previously met in 2016.

Pfizer announced plans to exit its 32% ownership interest in Haleon, the new standalone company formed post-GSK demerger. This move aims to maximize shareholder value. The demerger, involving GSK transferring approximately 80% of its consumer healthcare business to GSK shareholders, will be completed by July 2022. Haleon will also pursue a listing on the New York Stock Exchange. Key legal and financial advisors, including Morgan Stanley and Guggenheim Securities, are engaged in the process. This strategic decision aligns with Pfizer's focus on innovative medicines and vaccines.

Pfizer Inc. (NYSE: PFE) will host a live webcast on June 6, 2022 at 3:45 p.m. EDT featuring Angela Hwang and Aamir Malik discussing initiatives on expanding access and affordability for Pfizer’s medicines and vaccines. Investors can register and access the webcast via Pfizer's investor website. A transcript will be available within 24 hours post-event. The company emphasizes its commitment to quality healthcare and responsible collaboration worldwide.

Pfizer (NYSE: PFE) announced that its investigational therapy ervogastat (PF-06865571) and clesacostat (PF-05221304) for treating non-alcoholic steatohepatitis (NASH) with liver fibrosis has received Fast Track designation from the FDA. This designation aims to expedite the review of therapies addressing unmet medical needs. Phase 2a trial results showed a significant reduction in liver fat and a favorable safety profile. Pfizer is also conducting an ongoing Phase 2 trial (NCT04321031), with results expected in 2024, which will inform potential Phase 3 development.